



DATE CLINICAL BACKGROUND & STUDY DETAILS

3.23.26

History: Began breathing heavily ~6 hours prior to presentation. Occasional coughing/gagging, with accompanying lethargy. Grade 4/6 systolic murmur. Harsh lung sounds.

PATIENT

CXR report: cardiomegaly with suspect CHF.

Sadie Pence

Pertinent abnormal PE/Chem/CBC/UA Results: ALKP <10u/L, BASO 0.11K/uL, PDW 8.6fL.

Current medications: Furosemide (50mg/ml) 0.3ml IV q2hr, Pimobendan 2.5mg PO q12hr, O2 @15L/min

Sedation used: not required to complete full diagnostic ultrasound.

SPECIES

Pertinent previous ultrasound results: No previous.

Canine

STAT: Not requested.

Imaging performed by: Andi Parkinson, BS, RDMS.

BREED

RADIOGRAPHIC FINDINGS *NOTE: Images submitted for supplemental information only.

Jack Russell Terrier

Cardiomegaly with LA enlargement and concern for CHF.

SEX

ECHOCARDIOGRAM FINDINGS

FS

2D, m-mode, color flow and doppler imaging is available. The mitral valve is diffusely thickened with prolapse into the left atrial lumen. There is severe eccentric mitral regurgitation present. The MR velocity is normal. There is severe left atrial enlargement. There is mild left ventricular dilation. Left ventricular systolic function is hyperdynamic. Normal right heart. Mild thickening of the tricuspid valve with no TR. The aortic valve appears trileaflet with normal mobility. Trace AI. There is normal systolic flow velocity across the aortic valve. The main pulmonary artery is normal in diameter. The pulmonic valve is normal in appearance. Flow through the RVOT/PV is normal in velocity. Trace PI. No pericardial/pleural effusion or cardiac masses are seen.

AGE

3.22.15

WEIGHT

13.85lbs

CARDIAC CHART

INTERPRETED BY

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)
NORMAL PARAMETER	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
PATIENT	4.7		NM	2.1	51	83	NM
CANINE CARDIAC PARAMETERS	HR (BPM)	AV VMAX (m/s)	PV MAX (m/s)	BODY WEIGHT (kg)	LA 2D short axis Base view (cm)	LVIDd Avg; 2D and m-mode short axis (cm)	LVIDs Avg; 2D and m-mode short axis (cm)
NORMAL PARAMETER	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
PATIENT	150	1.2	0.9	6.3	3.0	3.7	1.8
*Normal chamber parameters expressed as a mean value (SD)				3	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
BODY WEIGHT DEPENDENT PARAMETERS				5	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
*Note: All measurements based upon multi-modal images and methods. An average value is reported.				10	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
				15	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
				20	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)
				25	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
				30	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)

Maggie Machen Lamy, DVM, DACVIM (Cardiology)

HOSPITAL NAME

Falls Road AH

REFERRING VET

Dr. Baker

INVOICE

47261

Adapted from June Boon, Veterinary Echocardiography, 1998

Rishniw M and Hollis NE, J Vet Intern Med 2000; 14:429-435	35	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
Hansson et al, Vet Rad and Ultrasound 2002	40	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
Bonagura et al. Echocardiography: principles of interpretation, Vet	50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS

The cause of the murmur is chronic degenerative valve disease causing severe mitral regurgitation. Severe left atrial enlargement indicates the risk for spontaneous congestive heart failure is elevated. Trace aortic insufficiency is noted, and a baseline BP is recommended. No additional issues are identified.

In light of the clinical signs, chest radiograph findings and severity of disease on echocardiogram, the diagnosis of congestive heart failure (stage C) is supported, and medications are warranted lifelong as below. Monitoring of sleeping respiratory rates will be paramount to screen for congestive heart failure at home. Cough suppression to improve QOL can also be considered (hydrocodone, 0.2-0.4mg/kg up to q4-6h PRN) for any residual mechanical cough in the face of normal sleeping respiratory rates. If able to be stabilized, the average survival time of canine patients with active pulmonary edema is 8-9 months on medications; however, most are able to maintain a good quality of life for that period on medications. Patient will always be at risk for recurrent CHF, development of arrhythmias/LA tear, syncope and/or sudden death in the future.

Omega fatty acid supplementation and mild salt restriction may also be of some long-term benefit. Monitor for acute progression of the cough, labored breathing, exercise intolerance or collapse episodes in the future.

Elective anesthesia is not advised, as there is high risk for complication.


PLAN

Continue Pimobendan 0.3mg/kg PO q12h. Continue Furosemide 1-2mg/kg PO q12h. Institute Spironolactone 1-2mg/kg PO q12h.

Monitor renal values and BP in 10-14 days, then every 3-4 months while on diuretics to ensure tolerance of medications. If doing well at home, renal values are reasonable and BP >130mmHg, administer ACEI 0.5mg/kg PO q12h. Consider hydrocodone if needed for QOL.

Recommend conservative monitoring with a recheck echocardiogram in 6 months, sooner if any development of associated clinical signs occurs in the interim.

IMAGES



The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance, please contact me.

Maggie Machen Lamy, DVM
Diplomate of the American College of Veterinary Internal Medicine (Cardiology)
info@sonopath.com